[Guidelines on the urological management of the adult patient with spinal dysraphism (spina bifida)].

Recommandations sur la gestion du risque et la prise en charge urologique du patient adulte atteint de dysraphisme spinal (spina bifida).
Complications Dysraphisme spinal Incontinence urinaire Neurogenic Neurogène Quality of life Qualité de vie Spina bifida Spinal dysraphism Urinary bladder Urinary incontinence Vessie

Journal

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
ISSN: 1166-7087
Titre abrégé: Prog Urol
Pays: France
ID NLM: 9307844

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 03 12 2022
accepted: 10 12 2022
pubmed: 8 1 2023
medline: 8 3 2023
entrez: 7 1 2023
Statut: ppublish

Résumé

Improved life expectancy and prenatal screening have changed the demographics of spina bifida (spinal dysraphism) which has presently become a disease of adulthood. Urinary disorders affect almost all patients with spinal dysraphism and are still the leading cause of mortality in these patients. The aim of this work was to establish recommendations for urological management that take into account the specificities of the spina bifida population. National Diagnosis and Management Guidelines (PNDS) were drafted within the framework of the French Rare Diseases Plan at the initiative of the Centre de Référence Maladies Rares Spina Bifida - Dysraphismes of Rennes University Hospital. It is a collaborative work involving experts from different specialties, mainly urologists and rehabilitation physicians. We conducted a systematic search of the literature in French and English in the various fields covered by these recommendations in the MEDLINE database. In accordance with the methodology recommended by the authorities (Guide_methodologique_pnds.pdf, 2006), proposed recommendations were drafted on the basis of this literature review and then submitted to a review group until a consensus was reached. Bladder dysfunctions induced by spinal dysraphism are multiple and varied and evolve over time. Management must be individually adapted and take into account all the patient's problems, and is therefore necessarily multi-disciplinary. Self-catheterisation is the appropriate micturition method for more than half of the patients and must sometimes be combined with treatments aimed at suppressing any neurogenic detrusor overactivity (NDO) or compliance alteration (anticholinergics, intra-detrusor botulinum toxin). Resort to surgery is sometimes necessary either after failure of non-invasive treatments (e.g. bladder augmentation in case of NDO resistant to pharmacological treatment), or as a first line treatment in the absence of other non-invasive alternatives (e.g. aponeurotic suburethral tape or artificial urinary sphincter for sphincter insufficiency; urinary diversion by ileal conduit if self-catheterisation is impossible). Spinal dysraphism is a complex pathology with multiple neurological, orthopedic, gastrointestinal and urological involvement. The management of bladder and bowel dysfunctions must continue throughout the life of these patients and must be integrated into a multidisciplinary context.

Identifiants

pubmed: 36609138
pii: S1166-7087(22)00514-0
doi: 10.1016/j.purol.2022.12.006
pii:
doi:

Types de publication

Review English Abstract Practice Guideline

Langues

fre

Sous-ensembles de citation

IM

Pagination

178-197

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Auteurs

A Manunta (A)

Centre de référence Spina Bifida-Dysraphismes, CHU Pontchaillou, Rennes, France.

B Peyronnet (B)

Centre de référence Spina Bifida-Dysraphismes, CHU Pontchaillou, Rennes, France. Electronic address: benoit.peyronnet@chu-rennes.fr.

C Olivari-Philiponnet (C)

Centre de référence Spina Bifida-Dysraphismes, CHU Pontchaillou, Rennes, France.

E Chartier-Kastler (E)

Service d'Urologie, GH Pitié-Salpétrière, APHP, Paris, France; Sorbonne Université, Paris, France; Service de médecine physique et réadaptation, Hôpital Raymond-Poincaré, APHP, Garches, France.

C Saussine (C)

Service d'urologie, les hôpitaux universitaires de Strasbourg, Strasbourg, France.

V Phé (V)

Service d'urologie, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, Paris, France.

G Robain (G)

Service de médecine physique et réadaptation, Hôpital Rotschild, APHP, Paris, France.

P Denys (P)

Service de médecine physique et réadaptation, Hôpital Raymond-Poincaré, APHP, Garches, France; Faculté de médecine Paris Ouest, Université de Versailles-Saint-Quentin-en-Yvelines, Garches, France.

A Even (A)

Service de médecine physique et réadaptation, Hôpital Raymond-Poincaré, APHP, Garches, France; Faculté de médecine Paris Ouest, Université de Versailles-Saint-Quentin-en-Yvelines, Garches, France.

E Samson (E)

Centre de référence Spina Bifida-Dysraphismes, CHU Pontchaillou, Rennes, France.

P Grise (P)

Service d'urologie, CHU Rouen, Rouen, France.

G Karsenty (G)

Aix-Marseille Université, urologie et transplantation rénale, Hôpital La Conception, AP-HM, Marseille, France.

J Hascoet (J)

Centre de référence Spina Bifida-Dysraphismes, CHU Pontchaillou, Rennes, France.

E Castel-Lacanal (E)

CHU Toulouse, service de médecine physique et de réadaptation et ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.

K Charvier (K)

Service de médecine physique et réadaptation, Hôpital Henry-Gabrielle, Hospices civils de Lyon, Saint-Genis-Laval, France.

A Guinet-Lacoste (A)

Sorbonne Université, GRC 001, GREEN Groupe de recherche clinique en neuro-urologie, AP-HP, Hôpital Tenon, 75020 Paris, France.

C Chesnel (C)

Sorbonne Université, GRC 001, GREEN Groupe de recherche clinique en neuro-urologie, AP-HP, Hôpital Tenon, 75020 Paris, France; Service de neuro-urologie et explorations périnéales, Hôpital Tenon, AP-HP, Paris, France.

G Amarenco (G)

Sorbonne Université, GRC 001, GREEN Groupe de recherche clinique en neuro-urologie, AP-HP, Hôpital Tenon, 75020 Paris, France; Service de neuro-urologie et explorations périnéales, Hôpital Tenon, AP-HP, Paris, France.

F Haffner (F)

ASBH, Association nationale Spina Bifida et Handicaps associés, 94420 Le Plessis Trevise, France.

M Haddad (M)

Service de chirurgie viscérale et urologie pédiatrique, AP-HM, Marseille, France.

L Le Normand (L)

Service d'urologie, CHU de Nantes, Nantes, France.

M-A Perrouin-Verbe (MA)

Service d'urologie, CHU de Nantes, Nantes, France.

B Perrouin-Verbe (B)

Service de médecine physique et réadaptation, CHU de Nantes, Nantes, France.

M De Seze (M)

Spécialiste en médecine physique et de réadaptation, Clinique St.-Augustin, Bordeaux, France.

A Ruffion (A)

Service d'urologie, Hospices civils de Lyon, Lyon, France.

X Gamé (X)

Département d'urologie, transplantation rénale et andrologie, CHU Rangueil, Université Paul-Sabatier, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH